Interest in the use and impacts of glucagon-like peptide-1 receptor agonists in rheumatology has exploded over the past year, a trend that appeared to crescendo at ACR Convergence 2025. There, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results